Zymeworks Inc.ZYME
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · zymeworks.com
Vancouver-based biotechnology company managing licensed assets, including Ziihera (zanidatamab) royalties, while developing multifunctional antibody therapeutics; currently acquiring Theravance Biopharma.
Key ratios
FCF / Sales
-32.6%2025
2024
-146.8%2023
-158.9%
Net margin
-126.3%TTM
2025
-76.6%2024
-160.8%2023
-156.1%
ROA
-15.8%TTM
2025
-14.3%2024
-14.6%2023
-14.0%
ROE
-42.0%TTM
2025
-26.7%2024
-30.5%2023
-24.8%
Revenue growth
38.9%2025
2024
0.4%2023
-81.6%
Recent news
U.S. FDA Approves Ziihera (zanidatamab-hrii) With and Without Tislelizumab Plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Track ZYME in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer